Hi Thymus,
All good & it’s actually really good news. I am hopeful that before a Ph3 happens for AD with Xanamem that the FDA will come on board with Accelerated Approval. It’s such a clinically unmet need globally, not just a diagnosis of AD but cognitive impairment in older people also & MH.
We know the huge benefits of both being an oral drug (more accessible to patients & QOL & care for them vs infusions in a hospital/outpatient setting plus the cost) as well as safety data. I know there is more happening in the AD space, but just WOW on the Biogen nightmare & patients dying on clinical trials from cerebral haemorrhage.
As you would have read, ILAP Passport is there for good reason, so congratulations to Dr Gourlay & team for securing this. Both NICE & MRHA are involved in granting this, so it’s already a good sign.
Beats old misery guts & his scotch saying he has no confidence lol! All that crap got put to bed long ago, with biomarkers for AD recently developed & doses…just salty & probably needs to drop a bit of Xanamem in his Scotch himself if he can’t see that the likes of NICE & KOL have found Xanamem & ACW to be worthy of an ILAP Passport.
Good to see you are still here Thymus.
- Forums
- ASX - By Stock
- ACW
- Ann: Actinogen awarded UK Innovation Passport for Xanamem
Ann: Actinogen awarded UK Innovation Passport for Xanamem, page-26
-
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.8¢ |
Change
-0.003(3.70%) |
Mkt cap ! $219.3M |
Open | High | Low | Value | Volume |
8.0¢ | 8.0¢ | 7.8¢ | $103.7K | 1.318M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 70000 | 7.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.9¢ | 564540 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3578 | 0.078 |
2 | 170000 | 0.077 |
2 | 100000 | 0.076 |
5 | 168658 | 0.075 |
2 | 41800 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 385780 | 3 |
0.081 | 217635 | 1 |
0.082 | 115000 | 2 |
0.083 | 22000 | 1 |
0.084 | 410075 | 3 |
Last trade - 10.25am 30/07/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online